No Data
Express News | Enlivex Receives Israeli Ministry Of Health Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients With Thumb Osteoarthritis
Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Express News | Enlivex Therapeutics Releases Interim Data Readout From Phase I/II AllocetraTM Trial Showing; Three-Month Readout Showed Avg. Pain Reduciotn Of 64%, 33% Of Patients Reported Pain Resolution, 89% Of Patients Did Not Proceed With Knee Replacement Surgery
H.C. Wainwright Maintains Enlivex Therapeutics(ENLV.US) With Buy Rating, Cuts Target Price to $6
No Data
